RecruitingNot ApplicableNCT05613010

Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant

Leveraging Technology to Improve Medication Adherence in Adolescent and Young Adult Kidney or Liver Transplant Recipients: A Micro-Randomized Trial


Sponsor

Johns Hopkins University

Enrollment

65 participants

Start Date

Mar 19, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Can the investigators create an effective way to improve adherence to immunosuppressant medication and reduce rejection, graft loss, and death in adolescents and young adults who have undergone kidney or liver transplantation? The investigators' mobile technology intervention uses real-time electronic pillbox-assessed dose timing and text message prompts to address antirejection medication nonadherence when nonadherence is detected.


Eligibility

Min Age: 13 YearsMax Age: 25 Years

Inclusion Criteria2

  • Adolescents and young adults (13-25 years old) who underwent kidney or liver transplantation at least 6 months prior to enrollment
  • Currently prescribed tacrolimus or sirolimus.

Exclusion Criteria6

  • Currently receiving dialysis
  • Hospitalized for duration of study
  • Significant developmental or cognitive delay
  • No access to a mobile device that supports text messaging
  • Decline to use electronic pill box to monitor daily medication adherence
  • Non-English speaking

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALmHealth Messaging Intervention Group

Participants will receive an electronic pill box; the research team will instruct participants on how to use this device. Participants will be asked to use the electronic pill box for their prescribed medicines for the duration of the study (up to 16 months). During the 12-week micro-randomized trial, participants will be randomized within person to receive (1) adherence support text messages or (2) no text message after each missed dose, and (1) praise text message or (2) no text message after each on time dose. Dose timing will be determined based on participant report of when they typically take their tacrolimus or sirolimus medicine.


Locations(1)

Johns Hopkins

Baltimore, Maryland, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05613010


Related Trials